FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 1 ...

52周新低排行 | 股票名称 | 收盘价 | 最低价 | | 创低率 | | --- | --- | --- | --- | --- | | 新达控股(08471) | 0.048 | 0.047 | -21.67% | | | ＸＩ二南三星－Ｕ | 0.036 | 0.035 | -16.67% | | | (09347) | | | | | | ＸＩ二南三星(07347) | 0.281 | 0.278 | -15.24% | | | 烯石电车新材料(06128) | 0.063 | 0.060 | -14.29% | | | 智云健康(09955) | 0.750 | 0.710 | -10.13% | | | 台州水务(01542) | 1.000 | 1.000 | -9.09% | | | 大行科工(02543) | 31.940 | 31.520 | -8.90% | | | 冠城钟表珠宝(00256) | 0.140 | 0.140 | -6.67% | | | 佰泽医疗(02609) | 3.180 | 3.150 | -5.41% | | | 一脉阳光(02522) | 5.990 | 5 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 基於目前可得的資料，董事會認為預期虧損增加主要是由於本集團進行戰略 轉型重組業務模式，圍繞核心人工智能能力，重點打造高質量及可產生現金流 的增長。此導致就出售若干子公司確認大額減值虧損及錄得與交易對手方正 處於重大訴訟或接受司法調查的業務相關的一次性特定撥備。由於從利潤率 較低的醫療用品銷售業務戰略性剝離及轉型至聚焦於經營效率較高的人工智 能驅動型P2M業務，本集團於報告年度的經營活動現金流入淨額預期將介乎約 人民幣50百萬元至約人民幣80百萬元，而截至2024年12月31日止年度的經營活 動現金流出淨額則約為人民幣148.4百萬元。 本公告所載的資料僅基於本公司參考本公司目前可得的資料及本集團於報告 年度的未經審核綜合管理賬目後所作出的初步評估，並非基於經本公司獨立 核數師或董事會審核委員會審核或審閱的財務數據或其他資料。因此，上述數 據可能會有所調整。本集團於報告年度的實際財務業績可能與本公告所披露 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 1 ...

Group 1 - The core point of the article is that Hu Yue, an executive director of Zhiyun Health (09955.HK), increased his shareholding by purchasing 117,700 shares at an average price of HKD 1.05 per share, totaling approximately HKD 123,600 [1][2] - After the purchase, Hu Yue's total shareholding reached 117,700 shares, representing 0.02% of the company's issued shares [1][2]

Core Insights - The Chinese healthcare industry has undergone a significant transformation from 2020 to 2025, transitioning from a "golden era" of investment to a "bubble-clearing period" characterized by a K-shaped divergence in market performance [1][2][4]. Group 1: K-shaped Downward Trends - The collapse of previously successful business models, particularly in CXO, consumer healthcare, and internet healthcare, has led to substantial market value losses, with some companies experiencing declines of over 90% [4][7]. - The downturn is attributed to macroeconomic factors such as U.S. interest rate hikes and geopolitical tensions, as well as microeconomic issues like supply-demand imbalances and the disappearance of growth dividends [8][10]. - The CXO sector, once seen as a perpetual growth engine, has faced a 46.68% decline for WuXi Biologics and 44.47% for Tigermed, revealing the fragility of its business model reliant on continuous global financing [12][10]. - Consumer healthcare has suffered a "Davis double whammy," with companies like Yonghe Medical and Aier Eye Hospital seeing declines of 86.19% and 52.69%, respectively, as consumer spending shifts away from discretionary healthcare services [14][15]. - Internet healthcare companies, including Zhiyun Health and Dingdang Health, have also faced severe declines, with drops of 92.44% and 90.67%, as the market realizes that their revenue largely comes from online drug sales rather than innovative healthcare solutions [19][21]. Group 2: K-shaped Upward Trends - In contrast, companies with strong global rights and hard-core technology have thrived, with Keren Biotechnology and Kangfang Biopharma seeing increases of 518.33% and 166.72%, respectively, marking a shift towards biopharma and global market engagement [29][31]. - The rise of these companies signifies a new era where capital is attracted to firms that can demonstrate robust clinical data and global market potential, moving away from mere concepts [30][31]. - Even within struggling sectors, some companies like WuXi AppTec and Yuyue Medical have shown resilience, with increases of 113.36% and 28.75%, respectively, by focusing on high-tech, high-barrier services [34][35]. Group 3: Challenges Ahead - Despite the emergence of new leaders, significant challenges remain, including the risks associated with licensing agreements that may compromise long-term profitability [36][37]. - The ADC sector is experiencing a rush similar to the past PD-1 craze, raising concerns about market saturation and price competition, which could undermine future profitability [39][40]. - The ongoing "ice age" in the primary market poses a threat to innovation, as funding for early-stage companies has become increasingly scarce, potentially leading to a decline in new drug approvals in the coming years [42][43].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical sector experienced a weekly return of 7.81%, outperforming the CSI 300 index by 5.03%, ranking 6th among 31 primary sub-industry indices. The medical services sub-sector had the highest weekly increase of 12.34% [3][15] - The report highlights the impact of recent events such as Elon Musk's announcement regarding Neuralink's product mass production in 2026, Arrowhead Pharmaceuticals' promising clinical data for its siRNA therapy ARO-INHBE, and OpenAI's launch of "ChatGPT health," which have driven the sector's performance. The report suggests that while the brain-computer interface theme may be at a short-term emotional peak, AI medical applications still have room for growth [3][14] - Continuous investment in innovative drugs and related assets in the CXO and upstream life sciences sectors is recommended [3][14] Summary by Sections 1. Market Performance - The pharmaceutical sector's monthly return was 4.87%, outperforming the CSI 300 index by 1.37%, ranking 18th among 31 primary sub-industry indices. The medical services sub-sector had the highest monthly increase of 12.19% [15][20] 2. AI Medical Applications - AI applications in healthcare include AI+medical testing, AI+medical large models, AI+imaging, AI+e-commerce/precision marketing, and AI+gene sequencing, with notable companies such as KingMed Diagnostics, Dian Diagnostics, and BGI Genomics leading in these areas [4][16] 3. CXO and Upstream Life Sciences - Key global CXO leaders to watch include WuXi AppTec, WuXi Biologics, and Kelun Pharmaceutical. Domestic clinical CRO leaders include Tigermed and PPD. The report also highlights resource-based CXOs and upstream life sciences companies [5][16] 4. High-end Medical Devices - The report suggests focusing on companies involved in robotic applications, pharmaceutical equipment, and consumer medical devices, as demand is gradually recovering [5][16] 5. Innovative Drugs - Investment opportunities are identified in small nucleic acids, ADCs, and IO dual/multi-antibodies, with specific companies recommended for each category [6][16]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | ...

Core Insights - The company, Weimai, is facing significant challenges as it attempts to transition from a registration service platform to a "full-course management" model, particularly in the context of its upcoming IPO application to the Hong Kong Stock Exchange [2][10] Financial Performance - Weimai's revenue growth has stagnated, with reported revenues of 512 million yuan, 628 million yuan, and 653 million yuan for 2022, 2023, and 2024 respectively, showing a year-on-year growth of 22.7% in 2023 but a sharp decline to 3.98% in 2024 [3] - The company has incurred net losses of 414 million yuan, 150 million yuan, and 193 million yuan over the same period, with total losses amounting to 757 million yuan, which is 1.16 times the projected revenue for 2024 [3] - Operating cash flows have been negative, with net cash from operating activities reported as -243 million yuan, -83 million yuan, and -39 million yuan from 2022 to 2024, indicating that the current business model is not generating sufficient funds for operations [3] Research and Development - Weimai emphasizes its self-developed CareAI platform as a core competitive advantage, claiming coverage of over 1,000 diseases and service to approximately 500,000 patients [4] - However, R&D expenditures have halved from 61 million yuan in 2022 to 30 million yuan in 2024, representing only 4.6% of revenue, significantly below the industry average of over 8% [4] - The AI technology's effectiveness is questioned, as it relies on third-party technologies for its foundational models, and core services still depend heavily on human teams [4] Business Model and Partnerships - Weimai's deep integration with public hospitals distinguishes it from competitors like Alibaba Health and JD Health, having established "full-course management centers" with 157 hospitals and partnerships with over 4,700 medical institutions by the end of 2024 [5] - Despite the apparent stability of this model, it is fragile due to profit-sharing disputes and data security concerns raised by hospitals [5] - The company's revenue model relies on a prepayment package fee system, with about 30% of income coming from value-added services that require profit-sharing with hospitals, leading to high marginal costs and challenges in achieving economies of scale [5] Market Position and Competition - The full-course management market is projected to grow from 61.4 billion yuan in 2024 to 365.4 billion yuan by 2030, with a compound annual growth rate of 34.6% [8] - However, Weimai's market share is only 1.06% based on 2024 revenue, indicating a lack of a strong competitive moat in a highly fragmented market [8] - The company faces increasing competition from other players in the chronic disease management space, many of whom have already integrated with insurance systems, highlighting Weimai's commercial model weaknesses [8] IPO and Financial Pressure - Weimai's push for an IPO is seen as a strategic necessity due to pressure from investors, with some agreements containing clauses that trigger buyback options if the IPO is not initiated by the end of 2025 [7] - The company has 821 million yuan in cash and cash equivalents as of the end of 2024, which may support short-term operations, but the negative operating cash flow raises concerns about future financial stability [7] Conclusion - Weimai's innovative approach to integrating AI and public hospital services has potential, but it must address fundamental questions regarding cost control, scalability, and the correlation between technology investment and commercial returns to succeed in a challenging market environment [9][10]

Core Viewpoint - Zhiyun Health (09955) announced the appointment of Ms. Hu Yue as an executive director and a member of the board nomination committee, effective from December 27, 2025 [1] - Ms. Zuo Yinghui has resigned from her position as an executive director and will no longer be a member of the nomination committee, also effective from December 27, 2025, due to her desire to dedicate more time to other professional matters [1] Summary by Category - **Management Changes** - Ms. Hu Yue appointed as executive director and board nomination committee member effective December 27, 2025 [1] - Ms. Zuo Yinghui resigned from executive director position and nomination committee member effective December 27, 2025 [1] - **Reason for Resignation** - Ms. Zuo Yinghui's resignation is attributed to her intention to focus more on other professional commitments [1]